ACHV
Q4 2026 EPS Estimate
$-0.20
Nov 5, 2026 · Reports before open
Revenue Estimate
$11M
FY2028E EPS$0.10
FY2029E EPS$1.34

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
75
Score
6 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
6100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$12.00
+44.2%
Consensus
$13.00
+56.2%
Bull
$18.00
+116.2%
12-Month Target Range6 analysts
$12.00$13.00$18.00
Current $8.32Consensus
Current Price
$8.32
Upside to Consensus
$4.68

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+682.83%
EPS
FY2028
Rev+281.23%
EPS
FY2029
Rev+123.33%
EPS+1187.82%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$5M$35M$134M$300M$479M
Low$4M$9M$47M$117M$187M
High$5M$55M$291M$587M$936M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-64M$-29M$16M$59M$117M
Low$-68M$-46M$-13M$12M$24M
High$-59M$-12M$38M$131M$263M
EPS Avg$-1.46$-0.66$0.10$1.34$2.69
Low$-1.57$-1.05$-0.30$0.28$0.56
High$-1.36$-0.27$0.86$3.02$6.04
Analysts (Rev / EPS)6 / 78 / 89 / 84 / 54 / 5
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$11M$18M$4M$7M$20M$27M
Low$11M$18M$4M$7M$20M$27M
High$11M$18M$4M$7M$20M$27M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-19M$-20M$-16M$-13M$-11M$-10M
Low$-21M$-23M$-16M$-13M$-11M$-10M
High$-15M$-13M$-16M$-13M$-11M$-10M
EPS Avg$-0.20$-0.21$-0.17$-0.14$-0.11$-0.11
Low$-0.22$-0.25$-0.17$-0.14$-0.11$-0.11
High$-0.16$-0.14$-0.17$-0.14$-0.11$-0.11
Analysts (Rev / EPS)1 / 61 / 71 / 21 / 21 / 21 / 5

Earnings Surprises

Recent Analyst Actions

Aug 13, 2026Morgan Stanley
Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight
Target:$13.00
+94.3%from $6.69
Aug 12, 2026Raymond James
Achieve Life Sciences price target lowered to $18 from $20 at Raymond James
Target:$18.00
+170.3%from $6.66
Aug 12, 2026H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV)
Target:$12.00
+77.3%from $6.77
Jun 26, 2026Raymond James
Achieve Life Sciences resumed with a Strong Buy at Raymond James
Target:$20.00
+238.2%from $5.91
Apr 20, 2026Canaccord Genuity
Achieve Life Sciences initiated with a Buy at Canaccord
Target:$13.00
+205.9%from $4.25
May 13, 2024Oppenheimer
Achieve Life Sciences (ACHV) PT Lowered to $11 at Oppenheimer
Target:$11.00
+354.5%from $2.42
Nov 16, 2022Maxim Group
Maxim Group Maintains Buy on Achieve Life Sciences, Lowers Price Target to $8
Target:$8.00
+608.0%from $1.13
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.